TriplePoint Venture Growth BDC (TPVG) Announces 3.75M Share Offering

TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) today announced that it has commenced an underwritten offering of 3,750,000 shares of its common stock. In connection with the proposed offering, the Company intends to grant the underwriters for the offering an option to purchase up to an additional 562,500 shares of the Company’s common stock.

The Company expects to initially use all of the net proceeds from this offering to repay outstanding debt borrowed under its credit facility. However, through re-borrowing of the initial repayments under the credit facility, the Company intends to use the funds to make investments in accordance with its investment objectives and strategies, to pay its operating expenses and other cash obligations, and for general corporate purposes.

Wells Fargo Securities, Morgan Stanley, Keefe, Bruyette & Woods, A Stifel Company, UBS Investment Bank and Goldman Sachs & Co. LLC are acting as joint book-running managers for the proposed offering.

A shelf registration statement relating to the securities to be issued in the proposed offering is on file with and has been declared effective by the Securities and Exchange Commission (the “SEC”). The proposed offering may be made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained, when available, from any of the following investment banks: Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to [email protected]; Morgan Stanley & Co. LLC - Attn: Prospectus Department – 180 Varick Street, 2nd Floor - New York, NY 10014; Keefe, Bruyette & Woods, Inc., Attn: Capital Markets, 787 Seventh Avenue, 4th Floor, New York, NY 10019, telephone: 1-800-966-1559; UBS Securities LLC, Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by calling (888) 827-7275, or by email: [email protected]; Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing [email protected].

The preliminary prospectus supplement, dated August 4, 2022, and accompanying prospectus, dated May 26, 2021, each of which will be or has been filed with the SEC, contain a description of these matters and other important information about the Company and should be read carefully before investing. Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities in the proposed offering or any other securities nor will there be any sale of these securities or any other securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

You May Also Be Interested In

• Andersen prices secondary offering of 4.28M shares at $44 each
• Zipalertinib trial data to be presented at IASLC lung cancer conference
• PMGC Holdings announces 1-for-10 reverse stock split for Aug. 21